Alfred L. Garfall, MD, provided a deep dive into the phase 2 BMT CTN 1902 trial of ide-cel in multiple myeloma after transplant.
Jordyn Sava
Jordyn Sava is an editor for Targeted Oncology.
Articles by Jordyn Sava
An updated analysis on larotrectinib showed compelling data in TRK fusion thyroid carcinoma.
Abhishek Maiti, MD, discussed the EVICTION trial in AML and results presented during the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.
The PSMAddition trial shows 177Lu PSMA-617 significantly delays progression in mHSPC when added to hormone therapy, with a positive trend in overall survival.
If approved, ziftomenib could be the first FDA-approved Menin inhibitor for relapsed/refractory acute myeloid leukemia with an NPM1 mutation.
Benmelstobart alone or with anlotinib improved progression-free survival after chemoradiotherapy in unresectable stage III non–small cell lung cancer.
EBC-129 demonstrates early activity and manageable safety in patients with heavily pretreated pancreatic cancer, supporting further development.
Neoadjuvant PAXG led to a significant improvement in event-free survival vs mFOLFIRINOX in resectable or borderline resectable pancreatic ductal adenocarcinoma.
Nivolumab plus ipilimumab shows durable survival benefit over chemotherapy and monotherapy in mismatch repair-deficient colorectal cancer.
A molecular test identified patients with high-risk early lung cancer who significantly benefitted from adjuvant chemotherapy, improving survival without disease progression.
Terence M. Williams, MD, PhD, discussed the phase 1 DINOMITE trial of radiation therapy and papaverine in rectal cancer at City of Hope.
The FDA biologics license application for patritumab deruxtecan in EGFR+ NSCLC has been withdrawn following discussions with the agency.
The pivotal AMPLIFY trial aims to support FDA approval of ⁶⁴Cu-SAR-bisPSMA as a best-in-class imaging tool in prostate cancer.
A phase 1b trial plans to evaluate AKY-1189 for the treatment of Nectin-4–expressing tumors.
START and OneOncology launch 3 new early-phase trial sites, expanding access to new cancer research in community oncology settings.
The FDA cleared an investigational new drug application for AVZO-1418/DB-1418, and a phase 1/2 trial in advanced solid tumors will begin later this year.
Kat M. Aguilar, MPH, discussed findings on social determinants of health and cancer mortality and their practical implications for community oncology.
As the oncology community prepares for the 2025 American Society of Clinical Oncology Annual Meeting, anticipation is running high over a wave of potential practice-changing data sets to be unveiled.
The ASCO 2025 press briefing showcased early highlights in cancer therapy. Here’s what you need to know.
Neel Shah, MD, our first 2025 Oncology Icon, reflected on his journey from academic medicine to community oncology.
Manmeet Ahluwalia, MD, MBA, FASCO, discussed the significance of National Cancer Research Month and highlighted how ongoing cancer research directly impacts patient care.
Cohort 1 of the GTB-3650 phase 1 trial completed with no safety issues observed in patients with CD33-expressing hematologic malignancies.
Kat M. Aguilar, MPH, discussed the findings of the recent study evaluating the early adoption of the distress thermometer.
The ODAC deemed the results from TALAPRO-2 are not sufficient to conclude a favorable benefit-risk profile for adding talazoparib to enzalutamide in non-HRRm mCRPC.
Lisa Herms, PhD, discussed findings from a retrospective analysis from the US community oncology setting on biomarker testing for bladder cancer.
The FDA ODAC decided that the overall benefit-risk of the investigational therapy UGN-102 is not favorable in patients with recurrent low-grade, intermediate-risk NMIBC.
Manmeet Ahluwalia, MD, MBA, FASCO, discussed the importance of Brain Cancer Awareness Month for a community oncologist audience.
PT-112 monotherapy advances to phase 3 trial in metastatic castration-resistant prostate cancer after positive FDA end of phase 2 meeting.
Mack Roach III, MD, discussed a study on artificial intelligence’s generalizability for prostate cancer across racial groups.
Ashraf Z. Badros, MBChB, discussed the results from the AURIGA trial of maintenance therapy with daratumumab and lenalidomide in newly diagnosed multiple myeloma.